IRulya Therapeutics Inc. (IRLA) Stock Ticker
Market factors today
Unlock the full IRLA picture
About IRulya Therapeutics Inc.
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
IRLA stock facts
| Ticker symbol | IRLA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $32.2M |
| CEO | Brigette Roberts |
| Employees | 38 |
| Headquarters | New Haven, CA, US |
| IPO date | 2019-05-09 |
| Website | quincetx.com |
What you can see for IRLA on Tickr
Live IRLA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IRLA report.
Rankings
FAQ
What is the ticker symbol for IRulya Therapeutics Inc.?
The ticker symbol for IRulya Therapeutics Inc. is IRLA, listed on the NASDAQ.
What is IRLA?
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.